Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer Patients.

NCT00174655 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00174655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00174655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer Patients.
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 30, 1998
Completion date
September 30, 2011
Enrollment
2,887 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms